Integrating post-radiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.

[1]  Jun Ma,et al.  Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma , 2019, Nature Communications.

[2]  “Hey CIRI, What’s My Prognosis?” , 2019, Cell.

[3]  Ash A. Alizadeh,et al.  Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction , 2019, Cell.

[4]  J. Manola,et al.  Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Ying Sun,et al.  Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma. , 2019, International journal of radiation oncology, biology, physics.

[6]  Yingqin Li,et al.  Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. , 2019, The New England journal of medicine.

[7]  Jun Ma,et al.  Spontaneous remission of residual post‐therapy plasma Epstein–Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large‐scale, big‐data intelligence platform‐based analysis , 2019, International journal of cancer.

[8]  Brian O'Sullivan,et al.  The addition of pretreatment plasma Epstein–Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification , 2019, International journal of cancer.

[9]  M. Dowsett,et al.  Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Ying Sun,et al.  Proposed modifications and incorporation of plasma Epstein‐Barr virus DNA improve the TNM staging system for Epstein‐Barr virus‐related nasopharyngeal carcinoma , 2018, Cancer.

[11]  Jun Ma,et al.  Nasopharyngeal carcinoma , 2019, The Lancet.

[12]  Ying Sun,et al.  Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Likun Chen,et al.  Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. , 2018, The Lancet. Oncology.

[14]  A. King,et al.  Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Jiang,et al.  Sequencing-based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinoma , 2018, Proceedings of the National Academy of Sciences.

[16]  B. Costello,et al.  Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Sze,et al.  Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). , 2018, Oral oncology.

[18]  Ying Sun,et al.  Prognostic value of plasma Epstein–Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy , 2017, Chinese journal of cancer.

[19]  Chiun Hsu,et al.  Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. King,et al.  Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer , 2017, The New England journal of medicine.

[21]  Kelly Y. Kim,et al.  Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients. , 2017, International journal of radiation oncology, biology, physics.

[22]  Y. Mao,et al.  Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy , 2016, Scientific Reports.

[23]  Jun Ma,et al.  Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. , 2015, The Lancet. Oncology.

[24]  Gary S Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration , 2015, Annals of Internal Medicine.

[25]  S. Leung,et al.  Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  P. Royston,et al.  External validation of a Cox prognostic model: principles and methods , 2013, BMC Medical Research Methodology.

[27]  K. Ang,et al.  An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma , 2013, Clinical Cancer Research.

[28]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[29]  V. Grégoire,et al.  Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[31]  M. Pencina,et al.  On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data , 2011, Statistics in medicine.

[32]  K. Markou,et al.  National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010. , 2011 .

[33]  A. King,et al.  Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Dignam,et al.  Choice and interpretation of statistical tests used when competing risks are present. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  T. Mok,et al.  Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  I. Ernberg,et al.  Comparison of plasma Epstein–Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma , 2004, Cancer.

[37]  S. Leung,et al.  Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. , 2002, Journal of the National Cancer Institute.

[38]  S. Leung,et al.  Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. , 1999, Cancer research.

[39]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[40]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[41]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.

[42]  Pelayo Vilar,et al.  Nasopharyngeal Carcinoma , 1966 .